BEIJING, July 19, 2024 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported that it has furnished a current report on Form 6-K to disclose material development relating to its dispute with Juventas. For details, please visit below link:https://www.sec.gov/Archives/edgar/data/1962738/000110465924080958/tm2419826d1_6k.htmAbout CASI PharmaceuticalsC ...